Clinical Trials
17 trialsNCT06663787 2026-05-13
HER2 CR
Nagoya City University
Active not recruiting
NCT07524114 2026-05-11
SHERLOCK
University Health Network, Toronto
Recruiting
NCT04434040 2026-05-04
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07069595 2026-04-22
PREDICT-RD
UNC Lineberger Comprehensive Cancer Center
Phase 2 Recruiting
NCT06134375 2026-04-20
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Dartmouth-Hitchcock Medical Center
Phase 1/2 Recruiting
NCT04768426 2026-04-13
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Stanford University
Phase 2 Recruiting
NCT04841148 2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT03384914 2026-03-06
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting
NCT07025785 2026-01-15
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase NA Recruiting
NCT03945721 2025-09-29
UNITY
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT05196087 2025-07-02
NIP IT!
University Health Network, Toronto
Recruiting
NCT04674306 2025-05-23
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT06595966 2024-09-19
Exploratory Research on Constructing a Computational Biological Model Based on NGS for MRD After Breast Cancer Surgery
Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
NCT02306096 2024-02-09
SCAN-B
Lund University
Recruiting
NCT04130152 2022-10-25
PROMETEO II
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT01401959 2018-06-15
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
SCRI Development Innovations, LLC
Phase 2 Completed